scholarly journals OC131: Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for Borderline Ovarian tumors

2008 ◽  
Vol 32 (3) ◽  
pp. 285-286
Author(s):  
D. Franchi ◽  
S. Boveri ◽  
A. C. Testa ◽  
N. Colombo ◽  
M. Sideri
Keyword(s):  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Ultrasonographic Diagnosis ◽  
Borderline Ovarian Tumors

scholarly journals Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors

2016 ◽  
Vol 215 (6) ◽  
pp. 756.e1-756.e9 ◽  
Author(s):  
Dorella Franchi ◽  
Sara Boveri ◽  
Davide Radice ◽  
Rosalba Portuesi ◽  
Vanna Zanagnolo ◽  
...  
Keyword(s):  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Ultrasonographic Diagnosis ◽  
Borderline Ovarian Tumors

Borderline ovarian tumors: Long-term survival and preservation of fertility.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15508-e15508
Author(s):  
Natasha Gercovich ◽  
Carlos Garcia Gerardi ◽  
Ernesto Gil Deza ◽  
Eduardo L. Morgenfeld ◽  
Edgardo G. J. Rivarola ◽  
...  
Keyword(s):  
Young Patients ◽  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Population Characteristics ◽  
Borderline Tumor ◽  
Term Survival ◽  
Borderline Tumors ◽  
Borderline Ovarian Tumors ◽  
The Usa

e15508 Background: Borderline ovarian tumors, also called low-malignancy potential tumors, are infrequent tumors present predominantly in pre-menopause women. Their evolution after surgical treatment is generally very good. The main objective of this paper is to show the evolution of a group of borderline tumors treated at our institution. Methods: Between January 1, 2000 and January 1, 2010, 36 patients diagnosed with ovarian borderline tumors were examined by two independent pathologists, according to the guidelines established by the USA Association of Directors of Anatomic and Surgical Pathology. These patients were followed at IOHM and comprise this paper’s study group. Results: Population Characteristics: Mean Age: 41 years (Range: 20-85). Affected Ovary (Right: 17 pts; Left: 14 pts; Both: 5 pts). Pathology: Mucinous (17 pts), Serous (16 pts), Clear, Brenner and Endometroid Cells (1 pt each). Stages: IA (24 pts), IB (5 pts), IC (2pts), IIIA (4 pts), IIIC (1 pt). Five patients presented non-invasive peritoneal implants and three presented positive peritoneal liquid. All patients were surgically treated: 28 with total anexohisterectomy (TAH) and 8 with unilateral ooforectomy. No patient was given any chemotherapy or radiotherapy treatment. Four patients did not attend follow-up consultations and were lost after 4, 6, 12 and 29 months with no evidence of disease (NED). Thirty-two patients were followed bi-annually during the first five years and annually thereafter. One patient became pregnant after the surgery. All patients are alive and NED with an average follow up of 50 months (range: 29-133). Conclusions: 1) Although half the cases in the study were under 35 years old, there were 12 tumors present in patients over 50 years of age and 1 borderline tumor present in an 85 year old patient. 2) Surgically treated ovarian borderline tumors have a high chance of being curable without the need of chemotherapy or radiotherapy. 3) Conservative surgery in young patients allows a conservation of fertility, provided they are subject to an adequate follow-up.

Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years

2018 ◽  
Vol 28 (9) ◽  
pp. 1643-1649 ◽  
Author(s):  
Li Sun ◽  
Ning Li ◽  
Yan Song ◽  
Guixiang Wang ◽  
Zitong Zhao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retrospective Study ◽  
Recurrence Rate ◽  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Stage I ◽  
Clinicopathologic Features ◽  
Borderline Ovarian Tumors ◽  
Risk Factors For Recurrence

ObjectiveThis study aimed to evaluate the clinicopathologic features of mucinous borderline ovarian tumors (MBOTs), with an emphasis on the risk factors for recurrence.MethodsData of 76 patients with MBOT diagnosed and treated between 2000 and 2007 at a single institution were analyzed in this retrospective study. The clinicopathologic features of different tumor subgroups were analyzed, including pathology, surgical methodology, recurrence, and overall survival.ResultsThe median patient age was 40 years (13–85 years). Forty-six patients with gastrointestinal mucinous borderline tumors (intestinal MBOTs) (73.7%) and 20 patients with endocervical MBOT (26.3%) were identified. Forty radical surgeries and 26 conservative surgeries were performed. There were 74.6% patients (50/67) with stage I disease among the 67 patients who received comprehensive surgical staging.During a median follow-up time of 151 months, 9 recurrences were identified. Median duration from surgery to recurrence was 26.4 months (range, 13–50 months). There was no difference in recurrence rate between intestinal MBOT and endocervical MBOT (14.3% vs 5.0%; P > 0.05). The recurrence rate of stage III tumors was significantly higher than that of stage I (33.3% vs 8%; P < 0.05). The recurrence rate after conservative surgery was higher than that after radical procedures (21.4% vs 6.3%; P < 0.05).ConclusionsThe majority of patients with MBOT had a favorable prognosis. Patients with later-stage disease had a higher recurrence rate.

Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery

1994 ◽  
Vol 4 (1) ◽  
pp. 60-64 ◽  
Author(s):  
G. Zanetta ◽  
D. Trio ◽  
A. Lissoni ◽  
M. Pittelli ◽  
A. Di Lelio
Keyword(s):  
Young Patients ◽  
Conservative Surgery ◽  
Ovarian Tumors

scholarly journals Minimally invasive treatment options to borderline ovarian tumors

2016 ◽  
Author(s):  
Punita Bhardwaj ◽  
T. K. Das ◽  
S. Batra ◽  
Keyword(s):  
Early Stage ◽  
Treatment Options ◽  
Malignant Potential ◽  
Ovarian Tumors ◽  
Conservative Approach ◽  
Uncertain Malignant Potential ◽  
Invasive Treatment ◽  
Younger Women ◽  
Borderline Ovarian Tumors

Borderline Ovarian tumors are tumors of uncertain malignant potential. They have favour able prognosis. They occur in younger women and present at an early stage. They are difficult to diagnose preoperatively as macroscopic picture is a combination of benign and invasive ovarian tumors. Over the years surgical treatment has changed from radical to conservative approach without overlooking oncologic safety. Follows up is essential. Prolonged follow up (>10 yrs) is required because of later recurrences. Special attention is to be paid to the conserved ovary in follow up.

Fertility and recurrence results of conservative surgery for borderline ovarian tumors

2005 ◽  
Vol 97 (3) ◽  
pp. 845-851 ◽  
Author(s):  
Nurettin Boran ◽  
Aylin Pelin Cil ◽  
Gokhan Tulunay ◽  
Esmen Ozturkoglu ◽  
Sevgi Koc ◽  
...  
Keyword(s):  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumors

scholarly journals Borderline Ovarian Tumors: Fifteen Years’ Experience at a Scottish Tertiary Cancer Center

2018 ◽  
Vol 28 (9) ◽  
pp. 1683-1691 ◽  
Author(s):  
James May ◽  
Karolina Skorupskaite ◽  
Mario Congiu ◽  
Nidal Ghaoui ◽  
Graeme A. Walker ◽  
...  
Keyword(s):  
Malignant Transformation ◽  
Surgical Management ◽  
Early Stage ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Ovarian Malignancy ◽  
Borderline Ovarian Tumors ◽  
Gynecology And Obstetrics ◽  
Preoperative Serum

ObjectivesSince the recognition of borderline ovarian tumors (BOTs) in the 1970s, the management of this subset of epithelial ovarian tumors has presented a challenge to clinicians. The majority present at an early stage, but their diagnosis is often only made following surgery, hence the heterogeneity of surgical management. Borderline ovarian tumors are morphologically diverse, and their behavior is subsequently also heterogeneous. We aimed to assess recurrence rates and the rate of malignant transformation in patients diagnosed with BOT. Secondary objectives included a review of current management and assessment of tumor markers, stage, cyst dimensions, and the presence of micropapillary features as prognostic indicators of recurrence.MethodsThis retrospective cohort study included all patients treated with BOT between 2000 and 2015 in the southeast region of Scotland. Clinical, surgicopathological, and follow-up data were collated. Data were analyzed with reference to recurrence and malignant transformation.ResultsTwo hundred seventy-five patients underwent treatment for BOT in the study period. Surgical management was highly variable. A diagnosis of recurrent/persistent BOT or ovarian malignancy following initial treatment of BOT was rare, with only 12 (4%) of 275 cases. There were 7 cases (3%) of ovarian malignancy. Advanced International Federation of Gynecology and Obstetrics stage was the most prominent prognostic factor. Elevated preoperative serum CA-125 and the presence of micropapillary features correlated with advanced stage at presentation. With a lack of clear guidance, follow-up was highly variable with a median of 43 months (0–136 months).ConclusionsTo our knowledge, this study is the largest BOT cohort in the United Kingdom. Recurrent disease is rare in optimally staged, completely resected, early-stage BOT, without high-risk features. Caution is needed in women electing not to undergo completion staging after diagnosis and in those opting for a fertility-preserving approach. Thorough informed consent and clear plans for surveillance and follow-up are needed with consideration of delayed completion surgery as appropriate.

LONG TERM FOLLOW UP OF BORDERLINE OVARIAN TUMORS IN ONCOLOGIC CENTER IN WARSAW

2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 43.2-43
Author(s):  
P. Sobiczewski ◽  
M. Bidzinski ◽  
J. Radziszewski ◽  
P. Derlatka
Keyword(s):  
Ovarian Tumors ◽  
Borderline Ovarian Tumors ◽  
Long Term Follow Up

Impact of infertility treatment in patients with previous history of borderline ovarian tumors: Results of a multicenter study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 5055-5055
Author(s):  
A. Fortin ◽  
P. Morice ◽  
A. Thoury ◽  
C. Yazbeck ◽  
S. Camatte ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Early Stage ◽  
Case Reports ◽  
Previous History ◽  
Infertility Treatment ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumors ◽  
History Of

5055 Background: The use of infertility drugs (ID) in infertile patients treated conservatively for ovarian malignancies remains theoretically contraindicated. Few recent case reports seem to suggest that ID could be used in patients treated for a borderline ovarian tumors (BOT). The aim of this multicenter retrospective study was to report the outcomes of the largest series of patients with a previous history of a BOT who underwent the use of ID. Methods: A multicenter retrospective study was conducted among centers which participate in the French National Register on In Vitro Fertilization registry to evaluate the outcomes of patients with a previous history of a BOT treated with ID. Four criteria were defined to select cases: 1. Histologic confirmation of BOT, 2. The use of a conservative surgery, 3. The use of ID and 4. A follow-up ≥ 12 months after the end of infertility treatment. Results: Thirty cases fulfilled inclusion criteria. Infertility therapy began in November 1989. Disease stages were: I (n = 20), II /III with noninvasive implants (n = 8) and unknown in 2 cases. The mean number of cycles of ovarian induction per patient was 2.6 (range,1–10). After a median follow-up of 42 months after infertility treatment, 4 recurrences were observed (all of them were borderline tumors on a remaining ovary treated by surgery alone). All patients are currently disease-free. Thirteen patients have since become pregnant. The median interval between treatment of the BOT and the use of ID is shorter in patients who relapsed compared to patients who did not (5 versus 29 months; p=.07). Conclusions: These results suggest that infertility drugs could be safely used in patients who experience infertility after conservative management of an early-stage BOT. A minimal interval should be respected between treatment of the ovarian tumor and the use of infertility drugs in order to decrease the risk of recurrence. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document